Market Cap
$85.3M
ATRA
Atara Biotherapeutics, Inc.
$9.48 ▲ +12.06%
Prev close $8.46Market cap$85.3M
12-mo target$13.67 (+44.2%)
Insider Buying Cluster (2 insiders)4 New Institutional Positions3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ATRA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
25 funds
Inst. Value
$27.0M
Inst. Activity
4 buys / 3 sells
Insider Activity
$5.7M buy / $3.3M sell
Insider Net $
$2.4M
SEC Reports
9
Price chart 30d -0.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 4, 2026 Insider
Cherry Brian N bought 104,166 shares
Director @ $9.60 ($1000.0K)
Aug 17, 2026 Insider
Nguyen AnhCo sold 5,062 shares
President and CEO @ $8.08 ($40.9K)
Aug 10, 2026 earnings_calendar
ATRA Q2 2026 Earnings Scheduled — 2026-08-10
Jul 22, 2026 Insider
Jul 3, 2026 SEC Redmile Group, LLC acquired via exercise 195,211 shares
Director
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026)
8-K — Impact 3/10
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — DOUBLED
687,718 shares ($7.9M)
Jun 30, 2026 Inst.
Jun 15, 2026 SEC MACKENZIE FINANCIAL CORP — TRIM
233,249 shares ($2.7M)
Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares of Atara Biotherapeuti
3 — Impact 2/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 18, 2026 | Freedom Broker | UPGRADE | Hold | 66% |
| May 8, 2026 | Canaccord Genuity | UPGRADE | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Aug 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jul 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jun 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 2 | 5 | 2 | 1 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 2 | 1 | 0 | 70% | |
| Mar 1, 2026 | 2 | 5 | 3 | 1 | 0 | 64% | |
| Feb 1, 2026 | 0 | 1 | 4 | 2 | 2 | 11% |
Price targets
Where 3 covering analysts think ATRA trades over the next 12 months.
$13.67 +44.2% upside Strong Buy
Current$9.48 Low$10.00 Median$13.00 High$18.00 3 analysts
$10.00$18.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 0 bullish, 0 bearish, 2 mixed, 7 neutral · avg impact 3.8/10.
NEUTRAL8-K3/10
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effec
Jul 3, 2026
NEUTRAL32/10
Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares of
Jun 15, 2026
MIXEDCLUSTER5/10
Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of sh
May 11, 2026
NEUTRAL8-K4/10
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study w
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 10, 2026
earnings_calendar
ATRA Q2 2026 Earnings Scheduled — 2026-08-10
May 13, 2026
earnings_calendar
ATRA Q1 2026 Earnings Scheduled — 2026-05-13
May 8, 2026
short_interest
FTD: ATRA — 78,159 shares ($0.8M) failed to deliver
Settlement: 20260508, Price: $9.93, FTD Value: $776,118.87, ATARA BIOTHERAPEUTICS INC COM
May 7, 2026
short_volume
Short Volume: ATRA — 58.8% short (20.7M / 35.1M)
Short: 20,652,044 | Exempt: 189,190 | TRF Vol: 35,115,186 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
ATRA Q1 2026 Earnings Scheduled — 2026-05-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.22 | $-0.33–$-0.11 | 31.3% | -7.3% | 0↑ 1↓ | $0.0B | 2 |
| Next Q | $-0.19 | $-0.32–$-0.06 | 45.7% | -5.6% | — | $0.0B | 2 |
| Current FY | $-0.95 | $-1.27–$-0.63 | -137.0% | -8.0% | 0↑ 1↓ | $0.0B | 2 |
| Next FY | $1.54 | $0.53–$2.56 | 262.6% | +21.7% | — | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.220 | — |
| 7d ago | $-0.330 | +0.110 |
| 30d ago | $-0.205 | -0.015 |
| 60d ago | $-0.205 | -0.015 |
| 90d ago | $-0.300 | +0.080 |
Institutional ownership
Which big funds own ATRA (from quarterly 13F filings) and who is adding or trimming.
25 institutional holders with $27.0M total value (2,354,190 shares) as of 2026-Q2. Top holders: ADAGE, Point72, VANGUARD. Net buying activity: 4 institutions added/increased vs 3 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 850,000 | $9.8M | 36.1% | — |
| Point72 Asset Management, L.P. | 687,718 | $7.9M | 29.2% | DOUBLED +254.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 247,047 | $2.8M | 10.5% | — |
| MACKENZIE FINANCIAL CORP | 233,249 | $2.7M | 9.9% | TRIM -25.6% |
| BlackRock, Inc. | 84,455 | $969.5K | 3.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 75,128 | $862.9K | 3.2% | — |
| VANGUARD FIDUCIARY TRUST CO | 43,036 | $494.1K | 1.8% | ADD +28.0% |
| JANE STREET GROUP, LLC | 30,345 | $348.4K | 1.3% | DOUBLED +142.1% |
| STATE STREET CORP | 26,453 | $303.7K | 1.1% | — |
| NORTHERN TRUST CORP | 16,591 | $190.5K | 0.7% | ADD +34.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | DOUBLED | 194,264 | 687,718 | +254.0% | $7.9M |
| MACKENZIE FINANCIAL CORP | TRIM | 313,620 | 233,249 | -25.6% | $2.7M |
| VANGUARD FIDUCIARY TRUST CO | ADD | 33,621 | 43,036 | +28.0% | $494.1K |
| NORTHERN TRUST CORP | ADD | 12,340 | 16,591 | +34.4% | $190.5K |
| MILLENNIUM MANAGEMENT LLC | TRIM | 47,689 | 12,680 | -73.4% | $145.6K |
| UBS Group AG | NEAR_EXIT | 50,070 | 3,979 | -92.1% | $45.7K |
| CITIGROUP INC | DOUBLED | 1 | 97 | +9600.0% | $1.1K |
| MACKENZIE FINANCIAL CORP | DOUBLED | 58,668 | 313,620 | +434.6% | $1.5M |
| Point72 Asset Management, L.P. | DOUBLED | 18,296 | 194,264 | +961.8% | $918.9K |
| UBS Group AG | DOUBLED | 1,397 | 50,070 | +3484.1% | $236.8K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 27 transactions. Net $2.4M — $5.7M bought, $3.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Cherry Brian N | Director | BUY | 104,166 | $9.60 | $1000.0K |
| Aug 17, 2026 | Nguyen AnhCo | President and CEO | SELL | 5,062 | $8.08 | $40.9K |
| Jul 22, 2026 | Redmile Group, LLC | Director | EXERCISE | 195,211 | — | — |
| Jul 22, 2026 | Redmile Group, LLC | Director | EXERCISE | 55,387 | — | — |
| Jul 22, 2026 | Redmile Group, LLC | Director | TAX W/H | 60 | — | — |
| Jul 22, 2026 | Redmile Group, LLC | Director | EXERCISE | 101,089 | — | — |
| Jul 22, 2026 | Redmile Group, LLC | Director | EXERCISE | 38,735 | — | — |
| Jun 11, 2026 | Cherry Brian N | Director | AWARD | 24,000 | — | — |
| Jun 9, 2026 | Fust Matthew K | Director | AWARD | 12,000 | — | — |
| Jun 9, 2026 | Ciongoli Gregory Austin | Director | AWARD | 12,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ATRA.
Shares short
404,270
Settlement Sep 15, 2026
Change vs prior
-5.4%
Semi-monthly cycle
Days to cover
7.3
At avg daily volume
Of shares outstanding
≈4.0%
Estimate — not % of float
All ATRA filing & press-release reports (9)
- 8-K reportJul 3, 2026
- 3 reportJun 15, 2026
- CLUSTER reportMay 11, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 24, 2026
- S-3 reportMar 17, 2026
- 8-K reportMar 12, 2026
- CLUSTER reportMar 4, 2026
- 8-K reportMar 3, 2026